Cassava shareholders reject board declassification; director pay raised

FILANA THERAPEUTICS, INC.

Proposal to reduce board classification from 3 to 2 classes failed despite 91% of votes cast in favor, lacking 66 2/3% of outstanding shares.
Non-employee director annual cash retainer increased from $10,000 to $40,000; Board Chair gets additional $30,000.
Annual stock option grant for continuing directors raised from 10,000 to 26,500 shares; initial grants rise to 53,000.
Audit, Compensation, and Nominating Committee chairs receive $15,000, $10,000, and $8,000 annual cash fees respectively.
Two directors elected: Robert Anderson, Jr. (5.64M for) and Michael J. O'Donnell (4.54M for) to three-year terms.

item 5.02item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.